1. Egan AM, McPhillips D, Sarkar S, Breen DP. Malignant pleural effusion. QJM. 2014; 107:179–184.
Article
2. Glaziou P, Floyd K, Raviglione M. Global burden and epidemiology of tuberculosis. Clin Chest Med. 2009; 30:621–636. vii
Article
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.
Article
4. Park JY, Jang SH. Epidemiology of lung cancer in Korea: recent trends. Tuberc Respir Dis (Seoul). 2016; 79:58–69.
Article
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7–30.
Article
6. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975; 250:4007–4021.
7. Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 1984; 138:141–143.
Article
8. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001; 1:377–396.
Article
9. Lee CL, Hsiao HH, Lin CW, Wu SP, Huang SY, Wu CY, et al. Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics. 2003; 3:2472–2486.
Article
10. Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics. 2002; 1:91–98.
Article
11. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics. 2003; 3:36–44.
Article
12. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395–409.
Article
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129–2139.
Article
14. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013; 105:595–605.
Article
15. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693–1703.
16. Bhatt M, Kant S, Bhaskar R. Pulmonary tuberculosis as differential diagnosis of lung cancer. South Asian J Cancer. 2012; 1:36–42.
Article
17. Tyan YC, Wu HY, Su WC, Chen PW, Liao PC. Proteomic analysis of human pleural effusion. Proteomics. 2005; 5:1062–1074.
Article
18. Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G, et al. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 2005; 5:31–38.
19. Beckman G, Eklund A, Fröhlander N, Stjernberg N. Haptoglobin groups and lung cancer. Hum Hered. 1986; 36:258–260.
Article
20. Benkmann HG, Hanssen HP, Ovenbeck R, Goedde HW. Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered. 1987; 37:290–293.
Article
21. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 2009; 27:2787–2792.
Article
22. Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, et al. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One. 2013; 8:e57401.
Article
23. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009; 26:215–227.
Article
24. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Yukiue H, Kaji M, et al. Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer. 2002; 35:149–154.
Article
25. Yokota S, Yanagi H, Yura T, Kubota H. Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G(1)/S transition through early S phase. J Biol Chem. 1999; 274:37070–37078.
26. Yokota S, Yamamoto Y, Shimizu K, Momoi H, Kamikawa T, Yamaoka Y, et al. Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma. Cell Stress Chaperones. 2001; 6:345–350.
Article
27. Sauter ER, Nesbit M, Tichansky D, Liu ZJ, Shirakawa T, Palazzo J, et al. Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental human squamous epithelium. Int J Cancer. 2001; 92:374–381.
Article
28. Cernat RI, Mihaescu T, Vornicu M, Vione D, Olariu RI, Arsene C. Serum trace metal and ceruloplasmin variability in individuals treated for pulmonary tuberculosis. Int J Tuberc Lung Dis. 2011; 15:1239–1245. i
Article
29. Oikonomou N, Thanasopoulou A, Tzouvelekis A, Harokopos V, Paparountas T, Nikitopoulou I, et al. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. Thorax. 2009; 64:467–475.
Article
30. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005; 38:1543–1552.
Article